

Title (en)
APOE GENE THERAPY

Title (de)
APOE-GENTHERAPIE

Title (fr)
THÉRAPIE GÉNIQUE À BASE D'APOE

Publication
EP 4065600 A1 20221005 (EN)

Application
EP 20828741 A 20201125

Priority
• US 201962939999 P 20191125
• US 2020070822 W 20201125

Abstract (en)
[origin: WO2021108809A1] A gene therapy vector comprising an expression cassette coding for a mammalian apolipoprotein E that has a residue other than arginine at at least one of positions 112, 136, or 158, but is not a mammalian apolipoprotein E that has R112, R136 and R158 or a mammalian apolipoprotein E that has C112, R136 and C158, or coding for an antibody that binds to APOE4 or disrupts the binding of APOE to heparan sulfate proteoglycans, and methods of using the vector, are provided.

IPC 8 full level
C07K 14/775 (2006.01); **A61P 25/28** (2006.01)

CPC (source: EP IL KR US)
A61K 48/005 (2013.01 - KR US); **A61K 48/0075** (2013.01 - KR US); **A61P 25/28** (2017.12 - EP IL KR US); **C07K 14/775** (2013.01 - EP IL KR US); **C12N 15/113** (2013.01 - KR US); **C12N 15/86** (2013.01 - KR US); **C12N 2310/141** (2013.01 - KR US); **C12N 2750/14143** (2013.01 - KR)

Citation (search report)
See references of WO 2021108809A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
WO 2021108809 A1 20210603; AU 2020391518 A1 20220714; BR 112022010065 A2 20220906; CA 3162761 A1 20210603; CN 114829390 A 20220729; EP 4065600 A1 20221005; IL 293116 A 20220701; JP 2023502515 A 20230124; KR 20220107243 A 20220802; MX 2022006364 A 20220622; US 2023044351 A1 20230209

DOCDB simple family (application)
US 2020070822 W 20201125; AU 2020391518 A 20201125; BR 112022010065 A 20201125; CA 3162761 A 20201125; CN 202080081724 A 20201125; EP 20828741 A 20201125; IL 29311622 A 20220518; JP 2022530164 A 20201125; KR 20227021579 A 20201125; MX 2022006364 A 20201125; US 202017779812 A 20201125